Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company’s product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria.
Travere Therapeutics
Unlock to Claim this listing
Add / Modify Company
3.11
Overall Excellence Rating
Industry
Pharmaceuticals & BiotechnologyCategory
BiotechnologyESG/Ethical Impact
Travere Therapeutics Inc. is committed to reducing its environmental footprint. Through initiatives like waste reduction, energy efficiency improvements, and responsible supply chain practices, the company strives to minimize its environmental impact. Travere Therapeutics Inc. places a strong emphasis on social responsibility. The company actively supports community engagement and development, fostering partnerships that promote health and education, and contributing to local economies where it operates. Strong governance and ethical practices are integral to Travere Therapeutics Inc.’s operations. The company upholds high standards of transparency, accountability, and fairness in its decision-making processes, ensuring the trust of its stakeholders. Travere Therapeutics Inc.’s ESG efforts are closely aligned with its financial sustainability. By embracing responsible business practices and managing potential risks, the company aims to safeguard its long-term financial performance and create value for shareholders. Demonstrating an unwavering commitment to ethics and integrity, Travere Therapeutics Inc. places a strong emphasis on responsible business practices. By adhering to codes of conduct that promote honesty, fairness, and accountability, the company cultivates an environment of mutual respect and trust.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us
Awards Received
2023
Revenues
235000000
Website Traffic
Employee Rating
4.2
Customer Rating
Company Size
100-1000
ESG Risk Rating
3